BioAmber Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported adjusted net loss of $9.4 million, or $0.36 per share, paring an $8.6 million adjusted net loss during the same quarter last year. On a GAAP basis, the company recorded a $7.1 million net loss, or $0.27 per share, improving on an $8.1 million and $0.39 net loss last year. Revenue dropped 24.9% compared with year-ago levels to $352,000. The company incurred net financial income of $1.6 million as compared to a charge of $507,000 in the same period in 2014. The net financial income in the quarter was the result of $1.3 million non-cash gain related to changes in the fair market value of the warrants issued in connection with the company's initial public offering (IPO Warrants). Loss before income taxes was $8.459 million against $8.416 million a year ago.

For nine months, the company reported net cash used in operating activities was $22.491 million against $10.203 million a year ago. Acquisition of property and equipment was $62.465 million against $59.474 million a year ago. Net loss was $32.3 million against $43.0 million last year.